Cargando…
Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
BACKGROUND: Hepatitis B virus (HBV) and HIV coinfection is associated with risk of progression to chronic liver disease. We assessed liver stiffness in HBV-HIV coinfected youths. METHODS: A cross-sectional study in HBV-HIV coinfected youths aged 18 to 25 years who received a tenofovir (TDF)-containi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748531/ https://www.ncbi.nlm.nih.gov/pubmed/30798669 http://dx.doi.org/10.1177/2325958218823259 |
_version_ | 1783452110057111552 |
---|---|
author | Aurpibul, Linda Kanjanavanit, Suparat Leerapun, Apinya Puthanakit, Thanyawee |
author_facet | Aurpibul, Linda Kanjanavanit, Suparat Leerapun, Apinya Puthanakit, Thanyawee |
author_sort | Aurpibul, Linda |
collection | PubMed |
description | BACKGROUND: Hepatitis B virus (HBV) and HIV coinfection is associated with risk of progression to chronic liver disease. We assessed liver stiffness in HBV-HIV coinfected youths. METHODS: A cross-sectional study in HBV-HIV coinfected youths aged 18 to 25 years who received a tenofovir (TDF)-containing antiretroviral therapy regimen for >96 weeks. Measurements included HBV DNA level, HBV serology profiles, and transient elastography (TE). The cutoff for TE results included ≥5.9 kPa for F2-moderate fibrosis, ≥7.4 kPa for F3-severe fibrosis, and ≥9.6 kPa for F4-cirrhosis. RESULTS: From March to December 2016, 15 HBV-HIV coinfected youths with a median duration on TDF-containing regimens of 3.3 years were enrolled. Five (33%) youths had significant liver fibrosis, 3 with F2-moderate, 1 with F3-advanced fibrosis, and 1 with F4-cirrhosis. Other 5 without liver fibrosis had hepatitis B surface e antigen (HBsAg) and hepatitis B surface e antigen (HBeAg) loss. Higher mean alanine transaminase (ALT) was observed among the group with F2-F4 when compared to those with F0. CONCLUSION: Liver fibrosis was evidenced in HBV-HIV coinfected youths in Thailand. Transient elastography might be considered for those who do not achieve HBsAg loss or have persistent ALT elevation while on treatment. |
format | Online Article Text |
id | pubmed-6748531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67485312019-11-04 Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen Aurpibul, Linda Kanjanavanit, Suparat Leerapun, Apinya Puthanakit, Thanyawee J Int Assoc Provid AIDS Care Short Communication BACKGROUND: Hepatitis B virus (HBV) and HIV coinfection is associated with risk of progression to chronic liver disease. We assessed liver stiffness in HBV-HIV coinfected youths. METHODS: A cross-sectional study in HBV-HIV coinfected youths aged 18 to 25 years who received a tenofovir (TDF)-containing antiretroviral therapy regimen for >96 weeks. Measurements included HBV DNA level, HBV serology profiles, and transient elastography (TE). The cutoff for TE results included ≥5.9 kPa for F2-moderate fibrosis, ≥7.4 kPa for F3-severe fibrosis, and ≥9.6 kPa for F4-cirrhosis. RESULTS: From March to December 2016, 15 HBV-HIV coinfected youths with a median duration on TDF-containing regimens of 3.3 years were enrolled. Five (33%) youths had significant liver fibrosis, 3 with F2-moderate, 1 with F3-advanced fibrosis, and 1 with F4-cirrhosis. Other 5 without liver fibrosis had hepatitis B surface e antigen (HBsAg) and hepatitis B surface e antigen (HBeAg) loss. Higher mean alanine transaminase (ALT) was observed among the group with F2-F4 when compared to those with F0. CONCLUSION: Liver fibrosis was evidenced in HBV-HIV coinfected youths in Thailand. Transient elastography might be considered for those who do not achieve HBsAg loss or have persistent ALT elevation while on treatment. SAGE Publications 2019-01-31 /pmc/articles/PMC6748531/ /pubmed/30798669 http://dx.doi.org/10.1177/2325958218823259 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Short Communication Aurpibul, Linda Kanjanavanit, Suparat Leerapun, Apinya Puthanakit, Thanyawee Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title_full | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title_fullStr | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title_full_unstemmed | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title_short | Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen |
title_sort | risk of liver fibrosis in hepatitis b virus and hiv coinfected youths receiving tenofovir-containing antiretroviral regimen |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748531/ https://www.ncbi.nlm.nih.gov/pubmed/30798669 http://dx.doi.org/10.1177/2325958218823259 |
work_keys_str_mv | AT aurpibullinda riskofliverfibrosisinhepatitisbvirusandhivcoinfectedyouthsreceivingtenofovircontainingantiretroviralregimen AT kanjanavanitsuparat riskofliverfibrosisinhepatitisbvirusandhivcoinfectedyouthsreceivingtenofovircontainingantiretroviralregimen AT leerapunapinya riskofliverfibrosisinhepatitisbvirusandhivcoinfectedyouthsreceivingtenofovircontainingantiretroviralregimen AT puthanakitthanyawee riskofliverfibrosisinhepatitisbvirusandhivcoinfectedyouthsreceivingtenofovircontainingantiretroviralregimen |